Top Tweets for #CHECKMATE914
Different results from 2 phase 3 studies on adjuvant IO for mRCC... what's the reason? - @DrIacovelli
@SuyogCancer
#ASCOGU24 #Cancer #Checkmate914 #KEYNOTE564 #MetastaticRenalCarcinoma #Ocnology #OncoDaily
https://t.co/sdtoxzAL1B
Adjuvant nivo monotherapy vs PBO for localized #RCC at high risk of relapse after nephrectomy: Results from part B of the randomized, phase 3 #CheckMate914 trial. Presentation by @motzermd @MSKCancerCenter. #GU24 coverage by @zklaassen_md @GACancerCenter > https://t.co/y5YC2BLaiQ
@motzermd with a thorough overview of the #Checkmate914 data, nivolumab without signif disease free survival effect vs placebo. <10% T4 or N1 and no M1NED pops may be a clue? @ASCO #GU24 @OncoAlert
The #OncoAlertTopTweet π¨
Day 4β£of #ASCO23 π
Tweet by our @OncoAlert faculty @DrChoueiri πΊπΈ
Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC at high risk of post-nephrectomy relapse
Best, @weoncologists
Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A).
Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC at high risk of post-nephrectomy relapse #ASCO23 @OncoAlert
@tbivala1 give his take home messages for the 1] #SWOGS1011 surgical trial of standard vs extended lymphadenectomy 2] the #VESPER trial of dd-MVAC vs GC as perioperative chemo for MIBC 3] #CheckMate914 Adjuvant Nivo/Ipi in high risk #RCC after nephrectomy @ASCO #ASCO23
![apolo_andrea's tweet photo. @tbivala1 give his take home messages for the 1] #SWOGS1011 surgical trial of standard vs extended lymphadenectomy 2] the #VESPER trial of dd-MVAC vs GC as perioperative chemo for MIBC 3] #CheckMate914 Adjuvant Nivo/Ipi in high risk #RCC after nephrectomy @ASCO #ASCO23 https://t.co/8PIFipbOvo](https://pbs.twimg.com/media/Fx4eR5pX0AAgXg7.jpg)
![apolo_andrea's tweet photo. @tbivala1 give his take home messages for the 1] #SWOGS1011 surgical trial of standard vs extended lymphadenectomy 2] the #VESPER trial of dd-MVAC vs GC as perioperative chemo for MIBC 3] #CheckMate914 Adjuvant Nivo/Ipi in high risk #RCC after nephrectomy @ASCO #ASCO23 https://t.co/8PIFipbOvo](https://pbs.twimg.com/media/Fx4eR5oXsAAntco.jpg)
![apolo_andrea's tweet photo. @tbivala1 give his take home messages for the 1] #SWOGS1011 surgical trial of standard vs extended lymphadenectomy 2] the #VESPER trial of dd-MVAC vs GC as perioperative chemo for MIBC 3] #CheckMate914 Adjuvant Nivo/Ipi in high risk #RCC after nephrectomy @ASCO #ASCO23 https://t.co/8PIFipbOvo](https://pbs.twimg.com/media/Fx4eR5jWIAE-twd.jpg)
#ASCO23 Concluding a great GU session moderated by @NehaVapiwala & @mkbupathi
β
#Checkmate914 adjuvant IPI/Nivo benefit some w #RCC
β
#VESPER ddMVAC better than GC for perioperative MIBC
βοΈ@SWOG extLND no benefit and more toxic in UC
@motzermd Seth Lerner, Cristian Pfister
Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A).
Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC at high risk of post-nephrectomy relapse #ASCO23 @OncoAlert
Dr. @motzermd with an important presentation of #CHECKMATE914 Part A subgroup analyses.
@ASCO #ASCO23
While the overall trial showed no improved outcomes with the combination of Nivo/Ipi vs placebo, sarcomatoid, high grade, and PD-L1 positive patients seemed to derive benefit from adjuvant Nivo/Ipi.
@MSK_DeptOfMed @MSKCancerCenter @HemOncToday @HemOncFellows @Hemoncq @IMG_Oncologists @OncoAlert
@motzermd dives into the patient features, amount of treatment, and QOL of the phase 3 #CheckMate914 (part A) trial of Adjuvant Nivo/Ipi vs placebo for patients with localized high risk #RCC #renalcellcarcinoma after nephrectomy
@ASCO #ASCO23
Always a pleasure to record w @montypal as we re-hashed #ESMO22 β #PROSPER #IMMotion010 #Checkmate914 #COSMIC313 #EV103cohortK β give a listen @CancerDotNet!
https://t.co/V1116Fn8jc
π£ NEW PODCAST! @ILSONDavid @montypal and @TiansterZhang discuss #NewResearch from #ESMO22 in gastrointestinal and genitourinary cancers https://t.co/0WnMOcXJBz #CancerResearch #LiverCancer #ColorectalCancer #StomachCancer #KidneyCancer #BladderCancer and #ProstateCancer #CRCSM
Adjuvant nivolumab + ipilimumab vs PBO for localized #RCC at high risk of relapse after nephrectomy: results from the randomized, phase 3 #CheckMate914 trial. Presented by @motzermd @MSKCancerCenter. #ESMO22 written coverage by @WallisCJD @UofT > https://t.co/VfgTCznBk9 @myESMO
Surprising data from #Checkmate914 trial showing adjuvant ipi-nivo did not improve disease free survival for #kidneycancer. Grateful as always for the patients who participated to help us learn in this massive trial. #ESMO22 @myESMO @OncoAlert
Presidential-2 #ESMO22
Primary endpoint for phase 3 CM914 trial not met, nivo + ipi not superior to placebo--higher toxicity. No clear subgroups that benefit. Part-B: adjuvant nivo only is ongoing!
@motzermd
@myESMO @OncoAlert
A packed house to hear #JamesLarkin discuss perioperative #kidneycancer management! Highlighting populations w benefit in #Keynote564 and the 3 adjuvant/periop trials to look forward to at #ESMO22! #IMmotion010, #PROSPERRCC #Checkmate914
#ESMO22 is next week!! As always from @DrChoueiri, this list of GU oncology abstracts is high impact. Looking forward to #COSMIC313, #PROSPER, #IMmotion010, #Checkmate914, #EV103 cohort K, #PRO biomarkers, #PRESTO, and so much moreβ¦
As #ESMO22 is approaching, here are my list of Top 15 #GU Oncology presentations, just based on "Titles"...
This list may ultimately change after abstracts release
https://t.co/pJCTDQnzb4
@myESMO @KKronig @FedefedeFri
βοΈNegative results from #CheckMate914 Trial π« π₯²π€¦π»ββοΈ
Possible reasonβ¦.π€·π»ββοΈβ
- Not all anti PD1 are the same? (Nivo < Pembro)
- M1 pts in KN564 vs only M0 in CM914?
π§
Many other trials ongoing in #adjuvant #RCC⦠waiting for more data and more details!
JUST IN: adjuvant nivo+ipi (6 months) in high-risk RCC did not meet its primary endpoint of DFS. Press release by @bmsnews via @BusinessWire βBig News this am!
@OncoAlert
https://t.co/WtyFAMHQxl
#Nivolumab #Ipilimumab #CheckMate914 #ScienceLink
CCR localizado: Nivolumab + ipilimumab no alcanzaron objetivo primario de SLE, estudio CheckMate-914
https://t.co/TFwYHKXhFt
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.9M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.3M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.5M followers
KATY PERRY
@katyperry
89M followers
Taylor Swift
@taylorswift13
82.9M followers
Lady Gaga
@ladygaga
74.4M followers
Virat Kohli
@imvkohli
71.9M followers
Kim Kardashian
@kimkardashian
70.5M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.9M followers
Bill Gates
@billgates
64.6M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62.1M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers